Choice of fluids in severe septic patients - a cost-effectiveness analysis informed by recent clinical trials

Reviews on Recent Clinical Trials

Volumn 9, Issue 1, 2014, Pages 21-30

  Farrugia, Albert ^a,b,c   Bansal, Megha ^a   Balboni, Sonia ^a   Kimber, Mary Clare ^a   Martin, Gregory S ^d   Cassar, Josephine ^e  

^a Plasma Protein Therapeutics Association   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CANBERRA   (Australia)

Author keywords

Clinical trials; Colloids; Costs; Decision analysis; Fluid therapies; Sepsis

Indexed keywords

ALBUMIN; HETASTARCH; INFUSION FLUID; ALBUMINOID; CRYSTALLOID; HETASTARCH DERIVATIVE; ISOTONIC SOLUTION;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FLUID RESUSCITATION; HEALTH CARE QUALITY; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; LIFE EXPECTANCY; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEPSIS; SURVIVAL; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DECISION TREE; ECONOMICS; FLUID THERAPY; SEVERITY OF ILLNESS INDEX;

ALBUMINS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; ISOTONIC SOLUTIONS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 84901806984     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887108666131213120816     Document Type: Article

References (45)

1. Dellinger RP, Levy M, Rhodes A, Annane D, Gerlach H, Opal S, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41(1): 580-637.
2. Hilton A, Bellomo R. A critique of fluid bolus resuscitation in severe sepsis. Crit Care. 2012; 16(1): 302.
3. National Institutes of Health. Ongoing clinical trials on fluids in sepsis [Internet]. 2013 [cited 2013 May 21]. Available from: http://www.clinicaltrials.gov/ct2/results?term=fluids+AND+sepsis&Search=Search
4. Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, et al. Resuscitation fluid use in critically ill adults: an international crosssectional study in 391 intensive care units. Crit Care. 2010; 14: R185.
5. Vincent J, Gottin L. Type of fluid in severe sepsis and septic shock. Minerva Anestesiol. 2011; 77: 1190-6.
6. Ernest D, Belzberg AS, Dodek PM. Distribution of normal saline and 5% albumin infusions in septic patients. Critical care medicine. 1999; 27(1): 46.
7. Andrades MÉ, Morina A, Spasić S, Spasojević I. Bench-to-bedside review: Sepsis-from the redox point of view. Critical Care. 2011; 15(5): 230.
8. The SAFE Study Investigators. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Medicine. 2010; 37(1): 86-96.
9. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: A systematic review and meta-analysis*. Crit Care Med. 2011; 39(2): 386-91.
10. Charpentier J, Mira J. Efficacy and Tolerance of Hyperoncotioc albumin Administration in Septic patients: The EARSS Study. Intensive Care Med. 2011; 37(Supplement 1): S115 (0438).
11. Gattinoni L. Albumin in septic shock: The ALBIOS study. Lisbon; 2012 [cited 2013 Jun 19]. Available from: http://www.albuminppta.com/-sepsis-literature-database/304-albumin-administrationimproves-survival-in-severe-sepsis-and-septic-shock-the-albiosstudy-
12. McIntyre L, Fergusson DA, Rowe B, Cook DJ, Arabi Y, Bagshaw SM, et al. The Precise RCT: Evolution of an Early Septic Shock Fluid Resuscitation Trial. Transfusion Medicine Reviews [Internet]. 2012 [cited 2012 Jun 27]; Available from: http://www.sciencedirect.com/science/article/pii/S0887796311001209
13. Ensor C. A Critical Look at Colloids in the Intensive Care Unit. Society of Critical Care Medicine: Clinical Pharmacy and Pharmacology; 2010 [cited 2012 Jun 27]. Available from: http://www.sccm.org/SiteCollectionDocuments/CPP%20Newsletter%20April%202010.pdf
14. Mizzi A, Tran T, Karlnoski R, Anderson A, Mangar D, Camporesi EM. Voluven, A New Colloid Solution. Anesthesiology Clinics. 2011; 29(3): 547-55.
15. Zarychanski R, Turgeon AF, Fergusson DA, Cook DJ, Hébert P, Bagshaw SM, et al. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med. 2009; 3(4): e196.
16. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. The Cochrane Collaboration, Dart AB, editors. Cochrane Database of Syst Rev [Internet]. 2010 Jan 20 [cited 2012 Jun 27]; Available from: http: //doi.wiley.com/10.1002/14651858.CD007594.pub2
17. Huang DT, Clermont G, Dremsizov TT, Angus DC. Implementation of early goal-directed therapy for severe sepsis and septic shock: A decision analysis. Critical Care Medicine. 2007; 35(9): 2090-100.
18. Bansal M, Farrugia A, Balboni S, Martin G. Relative survival benefit and morbidity with fluids in severe sepsis - a network metaanalysis of alternative therapies. Curr Drug Saf. 2013; 8(4): 236-45.
19. Annane D, Siami S, Jaber S, et al. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: The cristal randomized trial. JAMA. 2013; 310(17): 1809-17.
20. Bansal M, Farrugia A, Balboni S, Martin G. Relative survival benefit and morbidity with fluids in severe sepsis - A network metaanalysis of alternative therapies. Current Drug Safety (in press).
21. Vesconi S, Cruz DN, Fumagalli R, Kindgen-Milles D, Monti G, Marinho A, et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit Care. 2009; 13(2): R57.
22. Healthcare Cost and Utilization Project (HCUP). HCUP Nationwide Inpatient Sample (NIS) [Internet]. Rockville, MD.: Agency for Healthcare Research and Quality; 2010. Available from: http: //hcupnet.ahrq.gov/
23. Beck J, Pauker S, Gottlieb J, Klein K, Kassirer J. A Convenient Approximation of Life Expectancy (The "DEALE") II. Use in Medical Decision-Making. The American Journal of Medicine. 1982; 73: 889-97.
24. Rodríguez Barrios JM, Pérez Alcántara F, Crespo Palomo C, González García P, Antón De Las Heras E, Brosa Riestra M. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ. 2012; 13(6): 723-40.
25. Wang Z. Converting Odds Ratio to Relative Risk in Cohort Studies with Partial Data Information. [cited 2013 Apr 26]; Available from: http://star-www.st-andrews.ac.uk/cran/web/packages/orsk/vignettes/orsk_demo.pdf
26. Keith Berman. Albumin 2015: A Market Profile and Forecast of Albumin in the United States through the year 2015. USA: The Marketing Research Bureau Inc.; 2011 Jun.
27. Adrie C, Alberti C, Chaix-Couturier C, Azoulay É, de Lassence A, Cohen Y, et al. Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. Journal of Critical Care. 2005; 20(1): 46-58.
28. Perner A, 6S Trial Group and the Scandinavian Critical Care Trials Group. Hydroxyethyl Starch 130/0.4 versus Ringer's Acetate in Severe Sepsis. N Engl J Med. 2012; 1-11.
29. Bayer O, Reinhart K, Sakr Y, Kabisch B, Kohl M, Riedemann NC, et al. Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: A prospective sequential comparison. Critical Care Medicine. 2011; 39(6): 1335-42.
30. Moemen E. Continuous Renal replacement Therapy in Patients with Systemic Sepsis. Eg J Anaesth. 2009; 25: 453-61.
31. Rauf A, Long K, Gajic O, Anderson SS, Swaminathan L, Albright RC. Intermittent Hemodialysis Versus Continuous Renal Replacement Therapy for Acute Renal Failure in the Intensive Care Unit: An Observational Outcomes Analysis. Journal of Intensive Care Medicine. 2008; 23(3): 195-203.
32. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J of Med. 2008; 358(2): 125-39.
33. Shander A, Hofmann A, Ozawa S, Javidrozzi M. The True Cost of Red Blood Cell Transfusion in Surgical Patients [Internet]. San Francisco, CA; 2008 [cited 2012 Jun 26]. Available from: https: //ash.confex.com/ash/2008/webprogram/Paper11293.html
34. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. N Engl J Med. 2012; 367(20): 1901-11.
35. Food and Drug Administartion. Risks and Benefits of Hydroxyethyl Starch Solutions [Internet]. Bethesda, Maryland; 2012 [cited 2013 Jan 29]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsC onferences/UCM321588.pdf
36. European Medicines Agency. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl- starch [Internet]. 2013 [cited 2013 Jun 18]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Hydroxyethyl_starch-containing_solutions/human_referral_prac_000012.jsp&mid=WC0b01ac05805c516f
37. Wiedermann C, Dunzendorfer S, Gaioni L, Zaraca F, Joannidis M. Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Critical Care. 2010; 14: R191.
38. Van der Linden P, Icckx B. The effects of colloid solutions on hemostasis. CAN J ANESTH. 2006; 53(6): S30-S39.
39. Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B, et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov. 2007; 6(6): 437-42.
40. Wilkes NJ, Woolf R, Mutch M, Mallett SV, Peachey T, Stephens R, et al. The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg. 2001; 93(4): 811-6.
41. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012; 308(15): 1566-72.
42. Guidet B, Mosqueda GJ, Priol G, Aegerter P. The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock. Journal of critical care. 2007; 22(3): 197-203.
43. Food and Drug Administration. FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings [Internet]. 2013 [cited 2013 Jun 26]. Available from: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm
44. Quartin AA, Schein RMH, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. JAMA: the journal of the American Medical Association. 1997; 277(13): 1058-63.
45. Dreiher J, Almog Y, Sprung CL, Codish S, Klein M, Einav S, et al. Temporal trends in patient characteristics and survival of intensive care admissions with sepsis. Critical Care Medicine. 2012; 40(3): 855-60.